Isis Pharmaceuticals, Inc.

Antisense Therapeutics Limited

Ionis Pharmaceuticals, Inc.

Eli Lilly and Company

National University of Singapore

Genzyme Corporation

Kenneth Dobie

C. Frank Bennett

Kenneth W Dobie

Sanjay Bhanot

Susan M Freier

Ravi Jain

C Frank Bennett

Robert McKay

Brett P Monia

Mark J Graham

Rosanne M Crooke

Eric G Marcusson

Erich Koller

Sanjay K Pandey

Lex M Cowsert

Nicholas M Dean

James G Karras

George Tachas

Xing-Xian Yu

Eric E Swayze

Balkrishen Bhat

Stanley T Crooke

Richard Theodore Lee

Donna T Ward

Jeremy Graff

Christopher Belyea

Mark Heffernan

Jacqueline R Wyatt

Youngsoo Kim

Murielle M Veniant-Ellison

Kristina M Lemonidis

Richard A Lindberg

Scott W Henry

John G Geisler

John R Shutter

Brenda F Baker

Gene Hung

Huynh-Hoa Bui

Timothy A Vickers

Don W Cleveland

Madeline M Butler

Richard Alan Smith

Thomas P Condon

Jeffrey R Crosby

Joshua N Finger

William R Shanahan

Ian Popoff

Christopher John Wraight

George Arthur Werther

Alexander H Borchers

Susan Gregory

Adam Mullick

Ming-Yi Chiang

Frank C Bennett

Kathleen Myers

Cristopher John Wraight

Mark P Roach

Madelline M Butler

Wai Shiu Fred Wong

Thomas A Bell

Richard Lee

Kristina M Lemonidis Tarbet

Robert Mckay

Kristina Lemonidis-Tarbet

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing plasma lipids, plasma glucose and atherosclerotic plaques in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disease, or a symptom thereof.

Modulation of angiopoietin-like 3 expression

Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.

Modulation of nuclear-retained RNA

Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.

Compositions and methods for modulation of LMNA expression

Compounds, compositions and methods are provided for modulating the expression of apolipoprotein C-III. The compositions comprise oligonucleotides, targeted to nucleic acid encoding apolipoprotein C-III. Methods of using these compounds for modulation of apolipoprotein C-III expression and for diagnosis and treatment of disease associated with expression of apolipoprotein C-III are provided.

Modulation of apolipoprotein C-III expression

Antisense compounds, compositions and methods are provided for modulating the expression of superoxide dismutase 1, soluble. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding superoxide dismutase 1, soluble. Methods of using these compounds for modulation of superoxide dismutase 1, soluble expression and for treatment of diseases associated with expression of superoxide dismutase 1, soluble are provided.

Antisense modulation of superoxide dismutase 1, soluble expression

Provided herein are methods, compounds, and compositions for reducing expression of ApoCIII mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for increasing HDL levels and/or improving the ratio of TG to HDL and reducing plasma lipids and plasma glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease or metabolic disorder, or a symptom thereof.

Modulation of apolipoprotein CIII (ApoCIII) expression

Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.

Methods for slowing familial ALS disease progression

Compounds, compositions and methods are provided for modulating the expression of diacylglycerol acyltransferase 2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding diacylglycerol acyltransferase 2. Methods of using these compounds for modulation of diacylglycerol acyltransferase 2 expression and for diagnosis and treatment of diseases and conditions associated with expression of diacylglycerol acyltransferase 2 are provided.

Modulation of diacylglycerol acyltransferase 2 expression

Antisense compounds, compositions and methods are provided for modulating the expression of kinesin-like 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding kinesin-like 1. Methods of using these compounds for modulation of kinesin-like 1 expression and for treatment of diseases associated with expression of kinesin-like 1 are provided.

Antisense modulation of kinesin-like 1 expression

Compounds, compositions and methods are provided for modulating the expression of PTP1B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PTP1B. Methods of using these compounds for modulation of PTP1B expression and for treatment of diseases associated with expression of PTP1B are provided.

Antisense modulation of PTP1B expression

Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP1. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP1. Methods of using these compounds for modulation of eIF4E-BP1 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP1 are provided.

Modulation of eIF4E-BP1 expression

A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin &#x3b1;4 comprising administering to the animal a composition comprising from. 0.001 to 1000 &#x3bc;g per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin &#x3b1;4.

Topical administrations of antisense compounds to VLA-4 for the treatment of respiratory conditions

Growing community of inventors

Del Mar, CA, United States of America

Kenneth W Dobie